[1] 陈双双,马锐.多原发癌的研究进展[J].癌症进展,2019,17(8):883-886.
[2] WARREN S.Multiple primary malignant tumors.A survey of the literature and a statistical study[J].Am J cancer,1932,16:1358-1414.
[3] INSKIP P,CURTIS R.New malignancies following childhood cancer in the United States,1973-2002[J].Int J Cancer,2007,121(10):2233-2240.
[4] ALLAN J M,LOIS B T.Mechanisms of therapy-related carcinogenesis[J].Nat Rev Cancer,2005,5(12):943-955.
[5] CHEN S C,LIU C J,HU Y W,et al.Second primary malignancy risk among patients with gastric cancer:a nationwide population-based study in Taiwan[J].Gastric Cancer,2016,19(2):490-497.
[6] PARK S M,LI T,WU S,et al.Risk of second primary cancer associated with pre-diagnostic smoking,alcohol,and obesity in women with keratinocyte carcinoma[J].Cancer epidemiol,2017,47:106-113.
[7] KOWALCZYK J R,NURZYNSKA J,ARMATA J,et al.Incidence and clinical characteristics of second malignant neoplasms in children:a multicenter study of a polish pediatric leukemia/lymphoma group[J].Med Sci Monit,2004,10(3):CR117-CR122.
[8] 李楠.miR-16在上皮性卵巢癌中的表达及抑制卵巢癌细胞侵袭和转移的作用与机制研究[D].石家庄:河北医科大学,2018.
[9] FURSTENAU M,GIZA A,STUMPF T,et al.Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia[J].Am J Hematol,2021,96(12):E457-E460.[ZK)]
[10] [ZK (#]KUMAR V,GARG M,CHAUDHARY N,et al.An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States[J].PeerJ,2018,6:e4342.
[11] YOSHIDA M,NAKABAYASHI K,YANG W,et al.NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia[J].Blood Adv,2021,5(23):5420-5428.
[12] GHIMIRE K B,SHAH B K.Second primary malignancies in adult acute myeloid leukemia-a US population-based study[J].Anticancer Res,2014,34(7):3855-3859.
[13] LENZI L,LEE-JONES L,MOSTOFA M A,et al.Second primary malignancy after acute promyelocytic leukemia:a population-based study[J].Cancers,2020,12(12):3610.
[14] WELLINGTON F D S,NETO A C,ROSA L I,et al.Outcomes and second neoplasms in hairy cell leukemia:a retrospective cohort[J].Leuk Res,2019,83:106165.
[15] MOSER O,ZIMMERMANN M,MEYER U,et al.Second malignancies after treatment of childhood non-Hodgkin lymphoma-a report of the Berlin-Frankfurt-Muenster study group[J].Haematologica,2021,106(5):1390-1400.
[16] INAGAKI L,WARD K C.Survival after second primary lung cancer following non-Hodgkin lymphoma:a US population-based study[J].J Clin Oncol,2014,32(15):1536-1536.
[17] LEUNG W,SANDLUND J T,Hudson M M,et al.Second malignancy after treatment of childhood non-Hodgkin lymphoma[J].Cancer,2001,92(7):1959-1966.
[18] TADMOR T,LIPHSHITZ I,SILVERMAN B,et al.Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22466 survivors in Israel with 30 years of follow-up[J].Hematol Oncol,2017,35(4):599-607.
[19] CHATTOPADHYAY S,ZHENG G Q,SUD A,et al.Second primary cancers in non-Hodgkin lymphoma:family history and survival[J].Int J Cancer,2020,146(4):970-976.
[20] CHINEN Y,TANBA K,TAKAGI R,et al.Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma[J].Leuk Lymphoma,2020,61(14):3378-3386.
[21] MAJOR A,SMITH D E,GHOSH D,et al.Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis[J].Cancer,2020,126(1):189-201.
[22] YIN X,XU A,HUANG Z,et al.The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage Ⅰ/Ⅱ diffuse large B-cell lymphoma:an analysis of the surveillance,epidemiology,and end results database[J].Transl Oncol,2021,14(7):101106.
[23] XIAO H,HE J H,LIANG S M,et al.Racial/ethnic disparities on the risk of second malignant neoplasm among Hodgkin lymphoma survivors[J].Front Oncol,2022,11:5880.
[24] ABRAHAO R,BRUNSON A M,KAHN J M,et al.Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors[J].Leuk Lymphoma,2022,63(5):1091-1101.
[25] GIRI S,BHATT V R,VERMA V,et al.Risk of second primary malignancies in patients with follicular lymphoma:a United States population-based study[J].Clin Lymphoma MyelomaLeuk,2017,17(9):569-574.
[26] AMIOT A,JOOSTE V,GAGNIERE C,et al.Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma[J].Leuk Lymphoma,2017,58(9):2057-2064.
[27] YANG Y,YANG Y Q,YAN S.Risk and survival of second primary malignancies following diagnosis of gastric mucosa-associated lymphoid tissue lymphomas:a population-based study[J].Curr Probl Cancer,2021,45(6):100735.
[28] DELLA ROCCA A M,TONIN F S,FACHI M M,et al.Prognostic factors,survival analyses and the risk of second primary cancer:a population-based study on Burkitt lymphoma/leukemia[J].Diseases,2021,9(2):43.
[29] LOYA A,RAMACHANDRAN V,AYAZ T,et al.Second primary malignancies after ocular adnexal lymphoma diagnosis[J].BMC Ophthalmol,2021,21(1):1-11.
[30] ODDOU S,VEY N,VIENS P,et al.Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas:a report of six cases in a cohort of 171 patients from a single institution[J].Leuk Lymphoma,1998,31(1-2):187-194.
[31] ORMEROD A,FAUSEL C A,ABONOUR R,et al.Observations of second primary malignancy in patients with multiple myeloma[J].Clin Lymphoma Myeloma Leuk,2012,12(2):113-117.
[32] TURGUTKAYA A,YAVAŞOĞLU İ,ŞAHIN T,et al.Multiple myeloma and frequency of synchronous and second primary malignancies[J].JHematopathol,2021,14(3):197-203.
[33] LANGSETH Ø O,MYKLEBUST T Å,JOHANNESEN T B,et al.Patterns of previous and secondary malignancies in patients with multiple myeloma[J].Eur J Haematol,2021,106(4):529-536.
[34] SAHEBI F,IACOBELLI S,SBIANCHI G,et al.Incidence of second primary malignancies after autologous transplantation for multiple myeloma in the era of novel agents[J].Biol Blood Marrow Transplant,2018,24(5):930-936.
[35] CHATTOPADHYAY S,YU H,SUD A,et al.Multiple myeloma:family history and mortality in second primary cancers[J].Blood Cancer J,2018,8(8):1-4.
[36] LIU Y F,HOU H A,QIU H,et al.Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era?A population-based,retrospective cohort study in Taiwan[J].Sci Rep,2020,10(1):1-10.
[37] GIRI S,BARTH P,COSTA L J,et al.Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy:a population-based analysis[J].J Geriatr Oncol,2021,12(2):256-261.
[38] 王传芹.沙利度胺联合地塞米松或VAD方案治疗老年多发性骨髓瘤效果及安全性分析[J].现代医学,2019,12(47):1500-1502.
[39] YAMASAKI S,YOSHIMOTO G,KOHNO K,et al.Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation[J].Int J Hematol,2019,109(1):98-106.
[40] VICTORIA K,FREEDMAN I G.De novo myelodysplastic syndrome and subsequent diagnosis of primary solid tumors:evidence from the National Cancer Institute 2001-2011[J].Anticancer Res,2018,38(10):5819-5823.
[41] HONG J,LEE J H,BYUN J M,et al.Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms[J].Blood Adv,2019,3(22):3700-3708.
[42] THOMAS J W,JAMY O,SHAH M V,et al.Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval[J].Leuk Res,2022,112:106770. |
